Eric J. Topol, MD

The Influence of Body Mass Index on Outcomes and the Benefit of Antiplatelet Therapy following Percutaneous Coronary Interventio

08/01/2008

Amy Hsu , MD, MS;

Steven R. Steinhubl , MD;

Eric J. Topol , MD;

Robert V. Kelly , MD;

Obesity affects over 20% of the U.S. population and most countries in the developing world.1,2 It is an independent risk factor for premature coronary artery disease and is associated with an increase in cardiac morbidity and mortality,...

Obesity affects over 20% of the...

08/01/2008

Journal of Invasive Cardiology

Dual Antiplatelet Therapy with Clopidogrel and Aspirin After Carotid Artery Stenting

08/01/2008

Jay S. Yadav , MD;

Khaled M. Ziada , MD;

Marco Roffi , MD;

Christopher T. Bajzer , MD;

Samir R. Kapadia , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Debabrata Mukherjee , MD, MS;

Derek P. Chew , MBBS, MPH, PhD;

Eric J. Topol , MD;

Percutaneous carotid artery stenting is increasingly being used for the treatment of carotid artery stenosis, particularly in patients who are not candidates for surgical endarterectomy.1–3 In addition, it is currently being investigated as...

Percutaneous carotid artery...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention Reduces Ischemic Events without Affecting the Need

08/01/2008

Sorin J. Brener , MD;

Steven R. Steinhubl , MD;

Eric J. Topol , MD;

Danielle M. Brennan , MS;

Peter B. Berger , MD;

When clopidogrel is added to background aspirin therapy, it reduces the composite of cardiovascular death, myocardial infarction (MI) or stroke in patients with acute coronary syndromes (ACS)1 or percutaneous revascularization.2 The most...

When clopidogrel is added to...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Timing and Correlates of Very Early Major Adverse Clinical Events Following Percutaneous Coronary Intervention

08/01/2008

Peter B. Berger , MD;

James L. Orford , MBChB, MPH, MD;

Joseph Jozic , MD;

Amy Hsu , MD, MS;

Steven R. Steinhubl , MD;

Eric J. Topol , MD;

The timing of, and risk factors for, very early (< 24 hours) major adverse clinical events (death, myocardial infarction [MI], urgent target vessel revascularization [uTVR], and major bleeding) following percutaneous coronary intervention...

The timing of, and risk factors...

08/01/2008

Journal of Invasive Cardiology

A Randomized, Multicenter Trial Comparing a New, Low-Pressure Stent Versus a Conventional Stent: Primary Results from the CONSER

08/01/2008

Eric J. Topol , MD;

Danielle M. Brennan , MS;

Mark G. Midei , MD;

Dean J. Kereiakes , MD, FACC, FSCAI;

Dean Nukta , MD;

Donel Murphy , RN;

Sorin J. Brener , MD;

David J. Moliterno , MD;

David G. Rizik , MD, FACC, FSCAI;

As compared with balloon angioplasty alone, coronary stent implantation has resulted in improved clinical outcomes and lower clinical restenosis rates.1–3 The latter is not due to less neointimal proliferation, but rather to a larger initial...

As compared with balloon...

08/01/2008

Journal of Invasive Cardiology

The Combination of Enoxaparin, Glycoprotein IIb/IIIa Inhibitors and an Early Invasive Approach Among Acute Coronary Syndrome Pat

08/01/2008

Stephen G. Ellis , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

David J. Moliterno , MD;

David S. Lee , MD;

Eric J. Topol , MD;

W. Frank Peacock , MD;

ABSTRACT: Objectives. This study was designed to assess the feasibility and safety of enoxaparin in combination with glycoprotein (GP) IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) as part of an early invasive strategy...

ABSTRACT: Objectives. This study...

08/01/2008

Journal of Invasive Cardiology